Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gatipotuzumab, an antibody targeting MUC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Enoblituzumab, an antibody targeting B7-H3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Elezanumab, an antibody targeting RGMA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cosfroviximab, an antibody targeting Zaire Ebolavirus Glycoprotein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vopratelimab, an antibody targeting ICOS.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Valanafusp, an antibody targeting INSR.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Talacotuzumab, an antibody targeting IL3RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ladiratuzumab, an antibody targeting SLC39A6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Iscalimab, an antibody targeting TNFRSF5.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cusatuzumab, an antibody targeting CD70.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Camidanlumab, an antibody targeting IL2RA.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Volagidemab, an antibody targeting GCCR.